-+ 0.00%
-+ 0.00%
-+ 0.00%
Johnson & Johnson said in a study on non-small cell lung cancer, RYBREVANT combined chemotherapy reduced the risk of death by 43%.
Share
Listen to the news
Johnson & Johnson said in a study on non-small cell lung cancer, RYBREVANT combined chemotherapy reduced the risk of death by 43%.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending